Lisa Licitra

University of Milan — Italy

Medicine · Health Sciences

86h-index40.2kcitations920works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(459), Lung Cancer Treatments and Mutations(222), Cancer Immunotherapy and Biomarkers(138), Head and Neck Surgical Oncology(104), Salivary Gland Tumors Diagnosis and Treatment(103)

Publications915 total

Medical decision analysis for personalized oncology at the patient bedside
Tumori Journal·2026Open Access
Corrigendum to “Epithelial head and neck cancer survival in Europe: Geographical variation, time trends and long term survival” Eur J Cancer 229 (October) (2025) 115692
European Journal of Cancer·2025
Adjuvant anti-PD-1 therapy in high-risk cutaneous squamous-cell carcinoma: post hoc insights from the C-POST and KEYNOTE-630 studies
Immuno-Oncology Technology·2025Open Access
Figure S1 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Tables 3 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
2025Open Access
Supplementary Data1 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Tables 2 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
2025Open Access
Supplementary Data - "Tables 1" from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
2025Open Access
Figure S2 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Data_Figures 1 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
2025Open Access
Validation of a prognostic nomogram for locally advanced oropharyngeal carcinoma treated with intensity-modulated radiotherapy with/without systemic therapy
ESMO Open·2025Open Access
Impact of head and neck cancer on the income of Italian employees
BMC Public Health·2025Open Access
Spatial biomarker-driven deep learning model via digital pathology predicts response to PI3K inhibitor buparlisib in head and neck squamous cell carcinoma
2025Open Access
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma
Frontiers in Oncology·2025Open Access
Sinonasal Sarcomas Management: An International Consensus Statement
International Forum of Allergy & Rhinology·2025Open Access
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose
Journal of Clinical Investigation·2025· 3 citedOpen Access
Transcriptomic based prognostic model versus TNM 9th edition in HPV-positive oropharyngeal cancer
Oral Oncology·2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study
Journal of Clinical Oncology·2025· 7 citedOpen Access
A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: Results in the pre-immunotherapy era
European Journal of Cancer·2025· 1 cited
LBA48 BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Annals of Oncology·2025· 1 citedOpen Access
page 1 of 46Next →

Frequent Co-authors

Kevin J. Harrington(11), Makoto Tahara(11), Ezra E.W. Cohen(8), Paolo Bossi(8), Jérôme Fayette(7), Robert I. Haddad(7), Federica Perrone(7), Robert L. Ferris(6), Caroline Even(6), Barbara Burtness(6), Ricard Mesı́a(6), Laura D. Locati(6), J. Guigay(5), Everett E. Vokes(5), Nabil F. Saba(5), Maura L. Gillison(5), Denis Soulières(5), Gilberto de Castro(5), Danny Rischin(5), Rossella Elisei(5)